Helping The others Realize The Advantages Of "3
All enrolled sufferers who received at least one dose of zosuquidar or placebo during induction were monitored for your incidence of adverse events (439 sufferers, 219 on zosuquidar and 210 on placebo). The most typical adverse situations had been connected with the duration of extended and important myelosuppression as is predicted with induction